Abstract
Primary acute myeloid leukaemia (AML) blasts can be induced to differentiate into dendritic-like leukaemia cells (DLLC) by culture with certain cytokine combinations. DLLC offer potential for use as autologous vaccines based on their ability to present putative leukaemia-specific antigens to T cells. It has been reported, however, that in around 30–50% of AML cases the leukaemia cells are not capable of undergoing DLLC differentiation. The purpose of this study was to identify the features that represent successful DLLC differentiation and, for those cases shown to be resistant to cytokine-induced differentiation, to use differentiating agents in an attempt to overcome the differentiation block. Leukaemia cells derived from 42 patients with AML were cultured in vitro with cytokines GM-CSF, IL-4 and TNFα/CD40L. In 22 cases the leukaemic cells underwent DLLC differentiation based on characteristic morphological changes and expression of costimulatory and dendritic cell-associated molecules. Four cases were not evaluable because of poor viability over the culture period. The remaining 16 cases failed to show evidence of DLLC differentiation. Many of these differentiation resistant cases were associated with poor risk karyotypic features. Nine of the resistant cases were selected for further study. Differentiating agents trichostatin (TSA), azacytidine (AZA) and bryostatin (BRYO) were used in combination with cytokines for the first 96 h of the culture period. Bryostain (BRYO) alone was shown to be capable of overcoming differentiation resistance and allowing DLLC differentiation to proceed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Boyer MW, Waller EK, Bray RA, Unangst T, Johnson TS, Phillips C, Jurickova I, Winton EF, Yeager AM . Cytokine upregulation of the antigen presenting function of acute myeloid leukemia cells Leukemia 2000 14: 412–418
Brouwer RE, van der HM, Kluin-Nelemans HC, Zelderen-Bhola S, Willemze R, Falkenburg JH . The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses Hum Immunol 2000 61: 565–574
Charbonnier A, Gaugler B, Sainty D, Lafage-Pochitaloff M, Olive D . Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias Eur J Immunol 1999 29: 2567–2578
Choudhury BA, Liang JC, Thomas EK, Flores-Romo L, Xie QS, Agusala K, Sutaria S, Sinha I, Champlin RE, Claxton DF . Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses Blood 1999 93: 780–786
Cignetti A, Bryant E, Allione B, Vitale A, Foa R, Cheever MA . CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells Blood 1999 94: 2048–2055
Harrison BD, Adams JA, Briggs M, Brereton ML, Yin JA . Stimulation of autologous proliferative and cytotoxic T-cell responses by ‘leukemic dendritic cells’ derived from blast cells in acute myeloid leukemia Blood 2001 97: 2764–2771
Kohler T, Plettig R, Wetzstein W, Schmitz M, Ritter M, Mohr B, Schaekel U, Ehninger G, Bornhauser M . Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells Stem Cells 2000 18: 139–147
Oehler L, Berer A, Kollars M, Keil F, Konig M, Waclavicek M, Haas O, Knapp W, Lechner K, Geissler K . Culture requirements for induction of dendritic cell differentiation in acute myeloid leukemia Ann Hematol 2000 79: 355–362
Robinson SP, English N, Jaju R, Kearney L, Knight SC, Reid CD . The in vitro generation of dendritic cells from blast cells in acute leukaemia Br J Haematol 1998 103: 763–771
Redner RL, Wang J, Liu JM . Chromatin remodeling and leukemia: new therapeutic paradigms Blood 1999 94: 417–428
Kosgui H, Towatari M, Hatano S, Kitamura K, Kiyoi H, Kinoshita T, Tanimoto M, Murate T, Kawashima K, Saito H, Naoe T . Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy Leukemia 1999 13: 1316–1324
Yoshida M, Kijima M, Akita M, Beppu T . Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A J Biol Chem 1990 265: 17174–17179
Attadia V . Effects of 5-aza-2′-deoxycytidine on differentiation and oncogene expression in the human monoblastic leukemia cell line U-937 Leukemia 1993 7: 9–16
Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Di Fiore PP . 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias Blood 1984 64: 922–929
Kaneki M, Kharbanda S, Pandey P, Yoshida K, Takekawa M, Liou JR, Stone R, Kufe D . Functional role for protein kinase Cbeta as a regulator of stress-activated protein kinase activation and monocytic differentiation of myeloid leukemia cells Mol Cell Biol 1999 19: 461–470
Steube KG, Drexler HG . Differentiation and growth modulation of myeloid leukemia cells by the protein kinase C activating agent bryostatin-1 Leuk Lymphoma 1993 9: 141–148
Matsui H, Gladstone D, Vala M, Barber J, Brodsky R, Smith D, Jones R . Tumour cell terminal differentiation requires cell cycle inhibition combined with growth factors Blood 2000 96: 309a
Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, Rees JK, Stevens RF, Walker H . A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties Br J Haematol 1999 107: 69–79
Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G . Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T–T help via APC activation J Exp Med 1996 184: 747–752
Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML . T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal Immunol Today 1999 20: 561–567
Terheyden P, Straten P, Brocker EB, Kampgen E, Becker JC . CD40-ligated dendritic cells effectively expand melanoma-specific CD8+ CTLs and CD4+ IFN-gamma-producing T cells from tumor-infiltrating lymphocytes J Immunol 2000 164: 6633–6639
Acknowledgements
We thank Martin Waterfall for assistance in performing the allogeneic MLLR assays.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Roddie, P., Horton, Y. & Turner, M. Primary acute myeloid leukaemia blasts resistant to cytokine-induced differentiation to dendritic-like leukaemia cells can be forced to differentiate by the addition of bryostatin-1. Leukemia 16, 84–93 (2002). https://doi.org/10.1038/sj.leu.2402335
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402335
Keywords
This article is cited by
-
The Efficient Generation of Immunocompetent Dendritic Cells from Leukemic Blasts in Acute Myeloid Leukemia: A Local Experience
Pathology & Oncology Research (2009)
-
Quantification of ex vivo generated dendritic cells (DC) and leukemia-derived DC contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell-activation-procedures ex vivo or in vivo
Leukemia (2007)
-
An immune edited tumour versus a tumour edited immune system: prospects for immune therapy of acute myeloid leukaemia
Cancer Immunology, Immunotherapy (2006)
-
Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells
Leukemia (2004)